BioNetwork West 2015 (past event)
October 26 - 28, 2015
Contact Us: 1.888.482.6012
Change Compliance to Regulatory
08:00 - 08:45 Networking Breakfast
08:45 - 08:50 Welcoming Remarks
08:50 - 09:00 Chairperson’s Opening Address
Rick Clark
Technology Transfer Officer, Life SciencesUCLA Office of Intellectual Property & Industry Sponsored Research
09:00 - 09:30 Partnering Innovation Ice Breaker Roundtable Discussions
Speakers:
Kelly Powell VP, Corporate Development Orexigen Therapeutics
Chris Gambale President Global GXP Solutions
Gerry McCluskey Vice President of Business Development and Alliance Management Horizon Pharma
Priyanka Rohatgi Director Baxter Ventures
Kalpana Gupta Director of Business Development Regeneron
Kelly Powell VP, Corporate Development Orexigen Therapeutics
Chris Gambale President Global GXP Solutions
Gerry McCluskey Vice President of Business Development and Alliance Management Horizon Pharma
Priyanka Rohatgi Director Baxter Ventures
Kalpana Gupta Director of Business Development Regeneron
Get to know others with similar interests as you. Choose the topic most important to your business needs. You'll sit with 10 - 20 others seeking similar opportunities to debate the advantages and challenges assocatied with your chosen area, and make more connections!
#1 Valuation Strategies To Optimize Deal Terms And Structures
Kelly P. Powell, VP, Corporate Development, Orexigen Therapeutics
- Exploring valuation techniques to arrive at preferred deal terms (e.g. comparables, invested capital, discounted cash flow, etc.)
- When to use various techniques, as well as associated pitfalls
- How to use financial models to generate mutually beneficial deal structures
- Considerations for harmonizing your qualitative and quantitative partnering objectives
Christopher Gambale, President, Global GxP Solutions
- Building or modifying quality systems to incorporate new technology and new scientific platforms - Managing vendor quality risks through effective audit programs
- Improving speed to market through effective and efficient launches in a compliant manner
- Addressing existing Regulatory enforcement actions hamping your innovation and preventing new ones
- Preparation to move from an R&D setting or paper based system to an electronic system
- Essential elements necessary for a successful system implementation, cultural adoption, and long-term success in a complaint quality management system
- Quality strategy and project management
Gerry McCluskey, VP, Business Development and Alliance Management, Horizon Pharma
- How can BD and alliance management functions work most effectively together?
- How to avoid common pitfalls in alliance management
- Exploiting alliance management opportunities
Priyanka Rohatgi, Director, Baxter Ventures
- How has traditional venture capital changed over the past year, and what are expectations for the near- and far-term future?
- Exploring the emergence of venture capital groups associated with large provider organizations; what are their objectives in the current biopharma space?
- Discovering how the relationships among Big Pharma, biotechs, and VC are evolving
#5 In-Licensing: Winning Deals In A Highly Competitive Environment
Kalpana Gupta, Director of Business Development, Regeneron
Gerry McCluskey
Vice President of Business Development and Alliance ManagementHorizon Pharma
Program
09:30 - 10:10 PANEL: The Future Of Biopharma Deal-Making: How Health Economics, Compliance Changes, And Scientific Innovation Will Impact Us
Innovation drives our industry. From innovative therapies to innovations in healthcare, we must continue to evolve and respond to the changing, excititing times. Learn how these thought leaders are preparing for successful alliances now and into the future.
• How is health economics impacting the biopharma partnering and funding landscape?
• What compliance changes are being put in place from different governments across the globe?
• What therapeutic areas offer the most promise now or 10 years from now?
• Taking into account the external environment when creating collaborations
Pfizer
• How is health economics impacting the biopharma partnering and funding landscape?
• What compliance changes are being put in place from different governments across the globe?
• What therapeutic areas offer the most promise now or 10 years from now?
• Taking into account the external environment when creating collaborations
Melissa Fitzgerald
Senior Director, Global Scouting-San Diego, External Research & DevelopmentPfizer
1:1 Partnering Meetings
09:30 - 10:10 ContinuedProgram
10:10 - 10:35 Keynote: Creative Deal Making
Christoph Pittius has been involved in many innovative transactions throughout his career, both in- and out-licensing. In this presentation he’ll bring the most unique aspects of several different deals to light, highlighting the major issues that arose when carrying out original licensing transactions and steps that were taken to overcome the challenges. Arm yourself with novel strategies to be most effective in your partnerships.
1:1 Partnering Meetings
10:10 - 10:35 ContinuedProgram
10:35 - 11:05 Networking And Refreshment Break1:1 Partnering Meetings
10:35 - 11:05 ContinuedProgram
11:05 - 11:45 PANEL: Novel Collaborations Between Universities And Biopharma To Enhance Pipeline Development
Each year we explore the unique relationships between academics and pharma because innovations are quickly evolving and partnerships never look the same as they did last year. Gain insight into how these collaborations are changing and tools you can bring to your own dealmaking.
• How can pharma and biotechs best work with universities to fill pipeline gaps and access innovation?
• Discussing partnering, startup facilitation, incubators, and more
• What roles should universities and biopharma play for successful collaboration?
• Exploring recent pioneering deal structures put in place between academia and biopharma
• How can pharma and biotechs best work with universities to fill pipeline gaps and access innovation?
• Discussing partnering, startup facilitation, incubators, and more
• What roles should universities and biopharma play for successful collaboration?
• Exploring recent pioneering deal structures put in place between academia and biopharma
1:1 Partnering Meetings
11:05 - 11:45 ContinuedProgram
11:45 - 12:00 Biotech Spotlight: Resverlogix
Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com.
Resverlogix
Ken Lebioda
SVP Business & Market DevelopmentResverlogix
1:1 Partnering Meetings
11:45 - 12:00 ContinuedProgram
12:00 - 12:15 Biotech Spotlight: Compliment Corp.
Compliment Corporation, an NCI SBIR-funded company, is a start-up biotechnology company developing revolutionary therapeutics in oncology. Our proprietary technology platform generates novel engineered proteins derived from the non-immunogenic portion of adenoviruses that increase the efficacy and decrease the toxicity of widely used cancer therapies, such as monoclonal antibodies and chemotherapy drugs. Our lead product is the first therapeutic that selectively opens intercellular junctions between tumor cells allowing drug and biologic penetration into the tumors and applicable to small molecules, biologics and T-cell therapies. Our second product is an immune checkpoint technology targeting the complement system. It disables the complement-inhibitory protein CD46 with concomitant decrease of Treg numbers and thereby greatly enhances the function of certain biologics. Both technologies are in process development for cGMP manufacture at CMOs and have been proven effective in numerous models.
1:1 Partnering Meetings
12:00 - 12:15 ContinuedProgram
12:15 - 12:30 Biotech Spotlight: Telephus Medical1:1 Partnering Meetings
12:15 - 12:30 ContinuedProgram
12:30 - 12:45 Biotech Spotlight: Susavion Biosciences
Susavion Biosciences, Inc., is a privately-owned, pre-clinical stage biotechnology company that was founded to develop immunotherapeutic drugs suitable for a global market. Susavion’s technology is based on a novel platform—peptide mimetics of sugar-containing molecules—that are ligands of strategic regulatory receptors on immune cells. The technology unleashes the power of the human immune system to reset signals sent from dysfunctional disease states. Susavion’s drugs are potent stimulators of cell-mediated and humoral immunotherapy to overcome the ability of cancer cells to escape. Most importantly, they do not have the toxic effects that accompany chemo-therapy drugs and other immune therapies. Our drugs have broad application against cancers, have low toxicity, low cost, and thus are potential game changers. Susavion’s lead drug has demonstrated proof-of-concept in oncology studies, in particular suppression of accumulation of ascites associated with ovarian cancer, extended survival of mice with implanted glioma cells, and reduced immunosuppressive regulatory T cells in melanoma tumors.
1:1 Partnering Meetings
12:30 - 12:45 ContinuedProgram
12:45 - 13:00 Biotech Spotlight: Omniox
Omniox, an NCI SBIR-funded company, is an IND stage biotherapeutics company developing products that focus on hypoxic microenvironments in cancer, tissue ischemia, and critical care. Omniox is currently funded by The Wellcome Trust and the National Cancer Institute to develop its lead product, OMX-4.80P, to treat a range of hypoxic tumors in combination with chemoradiotherapy. The company is developing a second OMX product to treat focal tissue ischemia resulting from vaso-occlusions with the goal of saving tissue and preserving long-term organ function. The same product is effective in preventing heart failure in cases of acute global hypoxia. Omniox is evaluating financing and partnering options that support the initiation of multiple Phase 2 clinical programs by 2017.
1:1 Partnering Meetings
12:45 - 13:00 Continued13:00 - 14:00 Networking Luncheon
Program
14:00 - 14:40 PANEL: Risk Mitigation From Negotiation Through Execution
Speakers:
Mary Jo Struttmann Senior Director Alliance Manager Astellas Pharma US, Inc.
Christopher Seaton Senior Vice President of Negotiations Bayer HealthCare
John Adamou Head of US Strategic Transactions and Alliance Management Boehringer Ingelheim
Moderator:
Williams Ettouati Director, Industrial Relations & Development, Health Sciences Associate Cli University of California San Diego
Mary Jo Struttmann Senior Director Alliance Manager Astellas Pharma US, Inc.
Christopher Seaton Senior Vice President of Negotiations Bayer HealthCare
John Adamou Head of US Strategic Transactions and Alliance Management Boehringer Ingelheim
Moderator:
Williams Ettouati Director, Industrial Relations & Development, Health Sciences Associate Cli University of California San Diego
As the pace of scientific innovation accelerates and the IP landscape gets increasing complex, what are key value drivers in the prospect evaluation and valuation, how do you assign risk and what de-risking strategies do you employ when developing and negotiating partnerships?
• Staying in front of potential risks to keep things moving
• How is risk assigned, evaluated, and addressed?
• Risk mitigation strategies to employ when developing and negotiating partnerships
• Building the right team to evaluate and secure opportunities
University of California San Diego
• Staying in front of potential risks to keep things moving
• How is risk assigned, evaluated, and addressed?
• Risk mitigation strategies to employ when developing and negotiating partnerships
• Building the right team to evaluate and secure opportunities
Williams Ettouati
Director, Industrial Relations & Development, Health Sciences Associate CliUniversity of California San Diego
1:1 Partnering Meetings
14:00 - 14:40 ContinuedProgram
14:40 - 15:20 PANEL: How Open Innovation And Crowdsourcing Are Creating New Opportunities In BioPharma Development
Speakers:
Gregory Fond Director of External Science and Partnering Sanofi
Steven Bartz Director, Worldwide Licensing Merck
Chris Haskell Head of US Science Hub, Global External Innovation & Alliances Bayer HealthCare
Moderator:
Williams Ettouati Director, Industrial Relations & Development, Health Sciences Associate Cli University of California San Diego
Gregory Fond Director of External Science and Partnering Sanofi
Steven Bartz Director, Worldwide Licensing Merck
Chris Haskell Head of US Science Hub, Global External Innovation & Alliances Bayer HealthCare
Moderator:
Williams Ettouati Director, Industrial Relations & Development, Health Sciences Associate Cli University of California San Diego
Learn pioneering examples from leaders in Big Pharma about how open innovation and crowd sourcing are changing our industry. Be inspired and take fresh ideas back to your teams to leverage these technologies and social communities.
• Explaining crowd sourcing and how it is currently being used for early drug discovery and development
• Looking at open innovation and how its role has shifted over the past few years
• How are open innovation and crowdsourcing intersecting, and what does that mean for 5 years from now?
• How does your ecosystem need to evolve to fully leverage open innovation and crowdsourcing?
University of California San Diego
Bayer HealthCare
• Explaining crowd sourcing and how it is currently being used for early drug discovery and development
• Looking at open innovation and how its role has shifted over the past few years
• How are open innovation and crowdsourcing intersecting, and what does that mean for 5 years from now?
• How does your ecosystem need to evolve to fully leverage open innovation and crowdsourcing?
Williams Ettouati
Director, Industrial Relations & Development, Health Sciences Associate CliUniversity of California San Diego
Chris Haskell
Head of US Science Hub, Global External Innovation & AlliancesBayer HealthCare
1:1 Partnering Meetings
14:40 - 15:20 ContinuedProgram
15:20 - 15:50 Networking And Refreshment Break1:1 Partnering Meetings
15:20 - 15:50 ContinuedProgram
15:50 - 16:05 Biotech Spotlight: DianaPlant Sciences
DianaPlantSciences, Inc., a company based in Portland, Oregon, is a leader in the commercialization of potent “phyto-actives” sustainably sourced from plant cell culture for the nutrition, personal care, and pharma industries.
Plant cell culture technology includes the growth and propagation of plant cells from targeted plants in a controlled environment. Our proprietary process is completely non-GMO. We achieve our goal of obtaining plant cells with the highest concentration and distribution of targeted metabolites, that occur naturally in the plant, through a high throughput and accelerated process of natural selection. The benefits of plant cell culture include sustainability, standardization, and full traceability of plant source, as well as the opportunity to develop fully proprietary ingredients for a customer.
A company of the Symrise Group, DianaPlantSciences extends the Group’s capability in biotechnology. DianaPlantSciences continues to operate on our founding philosophy to deliver “Performance from Nature” and focuses the efforts of its scientists on truly unique solutions to help clients create maximal differentiation with no impact on the outside vegetal world. DianaPlantSciences is the recipient of the Nutrition Business Journal’s 2013 Innovation Award, the Nutritional Outlook’s Best of 2014 - Ingredient Supplier Award, and the laureate of Frost & Sullivan’s 2014 Global Visionary Innovation Leadership Award.
Plant cell culture technology includes the growth and propagation of plant cells from targeted plants in a controlled environment. Our proprietary process is completely non-GMO. We achieve our goal of obtaining plant cells with the highest concentration and distribution of targeted metabolites, that occur naturally in the plant, through a high throughput and accelerated process of natural selection. The benefits of plant cell culture include sustainability, standardization, and full traceability of plant source, as well as the opportunity to develop fully proprietary ingredients for a customer.
A company of the Symrise Group, DianaPlantSciences extends the Group’s capability in biotechnology. DianaPlantSciences continues to operate on our founding philosophy to deliver “Performance from Nature” and focuses the efforts of its scientists on truly unique solutions to help clients create maximal differentiation with no impact on the outside vegetal world. DianaPlantSciences is the recipient of the Nutrition Business Journal’s 2013 Innovation Award, the Nutritional Outlook’s Best of 2014 - Ingredient Supplier Award, and the laureate of Frost & Sullivan’s 2014 Global Visionary Innovation Leadership Award.
1:1 Partnering Meetings
15:50 - 16:05 ContinuedProgram
16:05 - 16:20 Biotech Spotlight: Spotlight Innovation
Spotlight Innovation Inc. (OTCQB: STLT) identifies, acquires and incubates companies that have unique intellectual property (IP) in the medical sector. The Company has relationships with the nation’s leading academic and institutional IP developers, and locates promising IP technologies with potential for market share capture. With strong support, development, resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We partner with proven sector leaders on commercialization once technologies are fully developed.
Spotlight Innovation Inc. subsidiary company Celtic Biotech Iowa, Inc. is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients. Additional information available at www.celticbiotech.com.
Spotlight Innovation Inc. subsidiary Memcine Pharmaceuticals, Inc. is an early-stage biotech company focused on enhancing vaccine efficacy to improve human and animal health globally. Memcine’s Immunoplex™ technology platform uses the body’s naturally occurring targeting system to deliver vaccine components. Additional information available at www.memcine.com.
Spotlight Innovation Inc. is based in West Des Moines, IA. Additional information available at www.spotlightinnovation.com.
Spotlight Innovation Inc. subsidiary company Celtic Biotech Iowa, Inc. is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients. Additional information available at www.celticbiotech.com.
Spotlight Innovation Inc. subsidiary Memcine Pharmaceuticals, Inc. is an early-stage biotech company focused on enhancing vaccine efficacy to improve human and animal health globally. Memcine’s Immunoplex™ technology platform uses the body’s naturally occurring targeting system to deliver vaccine components. Additional information available at www.memcine.com.
Spotlight Innovation Inc. is based in West Des Moines, IA. Additional information available at www.spotlightinnovation.com.
1:1 Partnering Meetings
16:05 - 16:20 ContinuedProgram
16:20 - 16:35 Biotech Spotlight: Asterias Biotherapeutics
Asterias Biotherapeutics is a development stage biotechnology company
focusing in regenerative medicine. We are developing therapeutics based
on two different platform technologies: dendritic cell cancer
immunotherapy and pluripotent stem cells. Near term, we are leveraging
these platforms to develop treatments to address significant unmet
medical needs in neurology and oncology. These mature programs are
focused on de-risked indications and are supported by robust
proof-of-concept pre-clinical and clinical data. Our three therapeutic
programs include:
- AST-VAC1 is an autologous immunotherapy treatment for Acute Myeloid Leukemia (AML) that has demonstrated improvement in long-term remission in a phase 2 trial. We are currently planning a phase 3 pivotal trial for accelerated approval in patients >60 years of age.
- AST-OPC1 are a neural cell type, which we manufacture from our pluripotent stem cell platform targeting spinal cord injury. A phase 1/2a trial is ongoing.
- AST-VAC2 is an allogeneic immunotherapy manufactured from our pluripotent stem cell platform that could have broad oncology applications. We are planning a phase 1 clinical trial in non-small cell lung cancer
We are a consolidated subsidiary of the BioTime family of companies, and are traded on the NYSE MKT under the ticker symbol AST.
- AST-VAC1 is an autologous immunotherapy treatment for Acute Myeloid Leukemia (AML) that has demonstrated improvement in long-term remission in a phase 2 trial. We are currently planning a phase 3 pivotal trial for accelerated approval in patients >60 years of age.
- AST-OPC1 are a neural cell type, which we manufacture from our pluripotent stem cell platform targeting spinal cord injury. A phase 1/2a trial is ongoing.
- AST-VAC2 is an allogeneic immunotherapy manufactured from our pluripotent stem cell platform that could have broad oncology applications. We are planning a phase 1 clinical trial in non-small cell lung cancer
We are a consolidated subsidiary of the BioTime family of companies, and are traded on the NYSE MKT under the ticker symbol AST.
1:1 Partnering Meetings
16:20 - 16:35 ContinuedProgram
16:35 - 16:50 Biotech Spotlight1:1 Partnering Meetings
16:35 - 16:50 ContinuedProgram
16:50 - 17:35 PANEL: The Human Element: Being Someone People Want To Make Deals With
High profile deals can be years in the making, starting from a career-long relationship that you've probably been strengthening at BioNetwork - we hear about these all the time. We also hear that people will not do business with others they can't trust or don't like. This panel will ensure you present yourself as someone people want to work with, and you gain skills to contribute to long-term relationship building.
• How much does a person’s likability come into play when deal making?
• What skill sets and personality traits make for the most successful BD executives?
• Developing your teams’ personal skills to ensure nothing gets in the way of finalizing a great deal
• How much does a person’s likability come into play when deal making?
• What skill sets and personality traits make for the most successful BD executives?
• Developing your teams’ personal skills to ensure nothing gets in the way of finalizing a great deal
